Try
Biodexa Pharmaceuticals plc
BDRXUnited States
15 filed reports · 522 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
15 reports · Dec 2017 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 120 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 20-FSEC EDGAR | 9 | 2,983 | Dec 2017 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 4 | 278 | Jun 2023 to Jun 2026 |
| Annual · 20-F/ASEC EDGAR | 1 | 1 | Dec 2022 |
| Interim · 6-K/ASEC EDGAR | 1 | 134 | Jun 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 6-K | Jun 30, 2026 | Sep 11, 2026 | 48 | Open |
| FY2025 | 20-F | Dec 31, 2025 | Mar 27, 2026 | 647 | Open |
| FY2025 Q2 | 6-K | Jun 30, 2025 | Sep 12, 2025 | 85 | Open |
| FY2024 | 20-F | Dec 31, 2024 | Apr 11, 2025 | 210 | Open |
| FY2024 Q2 | 6-K | Jun 30, 2024 | Sep 26, 2024 | 79 | Open |
| FY2023 | 20-F | Dec 31, 2023 | Apr 19, 2024 | 200 | Open |
| FY2023 Q2 | 6-K | Jun 30, 2023 | Sep 29, 2023 | 66 | Open |
| FY2022 | 20-F/A | Dec 31, 2022 | May 5, 2023 | 1 | Open |
| FY2022 | 20-F | Dec 31, 2022 | Apr 28, 2023 | 329 | Open |
| FY2022 Q2 | 6-K/A | Jun 30, 2022 | Oct 4, 2022 | 134 | Open |
| FY2021 | 20-F | Dec 31, 2021 | Apr 26, 2022 | 317 | Open |
| FY2020 | 20-F | Dec 31, 2020 | Apr 30, 2021 | 370 | Open |
Financial data
522 concepts · 3,396 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial500 concepts · 3,207 facts · Dec 2015 to Jun 2026
- Borrowings52 · Dec 2016 to Dec 2025
- Weighted average exercise price of outstanding options34 · Dec 2015 to Dec 2025
- Cash and cash equivalents32 · Dec 2015 to Dec 2025
- Equity32 · Dec 2015 to Dec 2025
- Liabilities (IFRS)30 · Dec 2015 to Dec 2025
- Assets (IFRS)28 · Dec 2015 to Dec 2025
- Current assets28 · Dec 2015 to Dec 2025
- Current liabilities28 · Dec 2015 to Dec 2025
- Current tax assets current28 · Dec 2015 to Dec 2025
- Equity and liabilities28 · Dec 2015 to Dec 2025
- Issued capital28 · Dec 2015 to Dec 2025
- Merger reserve (IFRS)28 · Dec 2015 to Dec 2025
- Noncurrent assets (IFRS)28 · Dec 2015 to Dec 2025
- Noncurrent liabilities28 · Dec 2015 to Dec 2025
- Number of outstanding share options28 · Dec 2015 to Dec 2025
- Property plant and equipment28 · Dec 2015 to Dec 2025
- Retained earnings28 · Dec 2015 to Dec 2025
- Share premium (IFRS)28 · Dec 2015 to Dec 2025
- Trade and other current payables28 · Dec 2015 to Dec 2025
- Trade and other current receivables (IFRS)28 · Dec 2015 to Dec 2025
- Current derivative financial liabilities (IFRS)26 · Dec 2015 to Dec 2025
- Number of share options exercisable in sharebased payment arrangement26 · Dec 2015 to Dec 2025
- Current borrowings and current portion of noncurrent borrowings (IFRS)25 · Dec 2015 to Dec 2025
- Longterm borrowings25 · Dec 2015 to Dec 2024
Segment20 concepts · 173 facts · Dec 2015 to Dec 2021
- Adjustments for depreciation expense14 · Dec 2015 to Dec 2021
- Administrative expense (IFRS)14 · Dec 2015 to Dec 2021
- Profit loss from operating activities14 · Dec 2015 to Dec 2021
- Research and development expense (IFRS)14 · Dec 2015 to Dec 2021
- Revenue14 · Dec 2015 to Dec 2021
- Amortisation expense12 · Dec 2015 to Dec 2020
- Finance costs10 · Dec 2016 to Dec 2021
- Finance income (IFRS)10 · Dec 2016 to Dec 2021
- Income tax expense continuing operations10 · Dec 2016 to Dec 2021
- Profit loss before tax10 · Dec 2016 to Dec 2021
- Revenue from government grants10 · Dec 2015 to Dec 2020
- Profit loss (IFRS)9 · Dec 2016 to Dec 2020
- Sales and marketing expense9 · Dec 2015 to Dec 2020
- Impairment loss recognised in profit or loss5 · Dec 2016 to Dec 2020
- Other income (IFRS)5 · Dec 2019 to Dec 2021
- Pipeline R&D5 · Dec 2015 to Dec 2021
- Cost of sales4 · Dec 2015 to Dec 2017
- Commercial2 · Dec 2017 to Dec 2018
- Operating Income1 · Dec 2016
- R&D Expense1 · Dec 2016
Geography2 concepts · 16 facts · Dec 2015 to Dec 2023
- Revenue13 · Dec 2015 to Dec 2022
- Revenue3 · Dec 2021 to Dec 2023
Segments
189 factsFigures broken down by business line, region, product or another axis the company reports on.
Segments3 members · 173 facts
- Pipeline R And D143 · Dec 2015 to Dec 2021
- Commercial28 · Dec 2015 to Dec 2018
- Pipeline rand d2 · Dec 2016
Geographical areas7 members · 16 facts
- Belgium5 · Dec 2020 to Dec 2023
- Europe Geographical Areas3 · Dec 2015 to Dec 2017
- US3 · Dec 2015 to Dec 2017
- GB2 · Dec 2016 to Dec 2017
- Rest Of The World1 · Dec 2020
- TR1 · Dec 2015
- United Kingdom1 · Dec 2020
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Management discussion (MD&A) commentary38 claims from 2 reports · Dec 2024 to Dec 2025
- Risk-factor changes9 claims from 1 reports · Dec 2025
- Risk factors149 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.